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Abstract
Recently, a newly emerged severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) caused a pandemic coronavirus disease (COVID-19). More than 10 
million confirmed cases and 503,867 associated deaths of SARS-CoV-2 have been 
reported worldwide to WHO in the end of July 2020. According to WHO guide-
lines, there is no effective therapy available for treating devastating SARS-CoV-2. 
Consequently, lack of evidence for appropriate treatment and vaccines has led to the 
re-emergence of convalescent plasma (CP) immunotherapy. Herein, we discuss the 
historical perspectives of CP against SARS-CoV, MERS-CoV, H1N1 pandemic and 
mainly the clinical outcomes of COVID-19 patients with respect to neutralizing anti-
bodies (nAbs). A brief possible clinical protocol for CP transfusion with its adverse 
effects and limitation were also highlighted. It is concluded that, CP transfusion with 
high neutralizing antibody titer administered in early course of disease significantly 
improved clinical outcomes in COVID-19 patients by reducing morbidity and mor-
tality. Thus, CP immunotherapy is considered as noteworthy candidate to be further 
re-evaluated as a most suitable therapeutic option against SARS-CoV-2 pandemic.
Keywords: SARS-CoV-2, COVID-19, Convalescent Plasma, Neutralizing antibodies, 
Pandemic
1. Introduction
In December 2019, a newly emerged respiratory diseases associated with 
 pneumonia from Wuhan, China caused by a initially named 2019 novel coronavirus 
(2019-nCoV) [1] and recently referred as severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2) producing coronavirus disease (COVID-19). Thus 2019-nCoV, 
caused a pandemic across the globe, the World Health Organization (WHO) declared 
it as a ‘Public Health Emergency of International Concern (PHEIC)’ on January 30th, 
2020. Considering its devasting threats worldwide, WHO declared SARS-CoV-2 as a 
pandemic spread on March, 2020 [2]. As per WHO guidelines, no effective therapy is 
available to treat devastating SARS-CoV-2, the treatment is mainly symptomatic and 
supportive. Thus, the current lack of evidence for effective treatment and vaccines, 
led to the re-emergence of classical and historical intervention called convalescent 
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plasma (CP) immunotherapy. Since the early 20th century, a passive CP immunization 
strategy has been used in prevention and control of infectious disease [3]. CP seems to 
be the first line of defense against the SARS-CoV-2, since it has been more successfully 
adapted in the treatment of SARS, MERS (Middle East Respiratory Syndrome) and 
H1N1 pandemic with significant efficacy and safety. In order to combat current devas-
tating pandemic, this review mainly highlights on the clinical immunotherapy studies 
conducted in the fields of neutralizing antibodies (nAbs) predominately present in 
convalescent plasma (CP) for the treatment and management of COVID-19.
2. Virology of SARS-CoV-2
Coronaviruses (CoVs) belongs to the family Coronaviridae and the order Nidovirales 
possessing a single-stranded, positive-sense RNA genome ranging from 26 to 32 kb in 
length [4]. SARS-CoV and SARS-CoV-2 comes under the genus Betacoronavirus of the 
subfamily Orthocoronavirinae and is further belongs to subgenus Sarbecovirus [5].
Based on the phylogenetic tree analysis, nucleotides of SARS-CoV-2 shares 96% 
sequence identity with the SARS-like (SL) virus named BatCoV-RaTG13/Bat-SL-
RaTG13 [6] and 88–88.2% identity [6–8] with bat-derived SARS-like coronaviruses 
named Bat-SL-CoV-ZC45 and Bat-SL-CoV-ZXC21, suggesting that bats are the most 
likely reservoir. Interestingly, the phylogenetic study showed that MERS-CoV and 
SARS-CoV were about 50% and 79% similar to SARS-CoV-2, respectively [6, 7]. 
The Spike (S) protein of SARS-CoV-2 was found to be approximately 75% homolo-
gous to the SARS-CoV spike [6].
The organization of the CoV genome contains a 5′-leader-UTR-replicase- 
S(Spike)- E (Envelope)- M(Membrane)- N(Nucleocapsid)-3′ UTR-poly(A) tail 
with accessory genes interspersed in the structural genes on the 3′ end of the 
genome [9]. In 5′ terminal, 2/3rd of viral RNA primarily locates the first ORF 
(ORF1a/b) which translates 2 polyproteins namely, pp1a and pp1ab, and encodes 
16 non-structural proteins (NSP), while the remaining ORFs encode accessory 
and structural proteins [10]. The structural proteins of SARS-CoV-2 contains 
spike (S), an envelope (E), membrane (M) and nucleocapsid (N) protein that are 
located at the one third 3′ terminal of the genome [11]. The critical step for SARS-
CoV-2 entry is binding of trimeric spike (S) glycoprotein to host cell angiotensin-
converting enzyme 2 (ACE2) receptors similar to that of SARS-CoV entry [6]. 
Coronavirus nAbs targets primarily surface spike glycoprotein that mediate viral 
entry into host cells. The symptoms of COVID-19 most commonly are fever, 
cough, myalgia or fatigue, dyspnoea, pneumonia and lesser common were sputum 
production, headache and diarrhea. The complication of SARS-CoV-2 are mostly 
acute respiratory distress syndrome (ARDS), followed by shock, myocardial 
dysfunction and acute kidney injury [12, 13]. A detailed overview of COVID-19 
disease progression was discussed, with particular reference to immunopathology 
and immunobiology [14].
SARS and MERS are caused by zoonotic coronaviruses that belong to the genus 
Betacoronavirus within Coronaviridae. SARS-CoV emerged in southern China in 2003 
and caused 8098 cases worldwide, including 774 related deaths with an estimated 
14–15% case-fatality rate [15]. In 2012, the first case of MERS occurred in Saudi 
Arabia. A sum of 2,494 cases and 858 related deaths with an overall case-fatality 
rate up to 34.4% [16]. More than 10 million confirmed cases of SARS-CoV-2 were 
reported globally by WHO, including 503,867 associated deaths as on the date of 
compilation 30th June-2020 (Figures 1 and 2). A total of 566,840 confirmed cases 
of SARS-CoV-2 were reported in India, including 16,893 associated deaths as on the 
date of compilation 30th June-2020 (https://covid19.who.int/) (Figures 3 and 4).
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Figure 1. 
Total number of cumulative SARS-CoV-2 cases and deaths across the globe during current pandemic. Source 
adapted from (https://covid19.who.int/). [accessed 2020-06-30].
Figure 2. 
Total number of daily new confirmed SARS-CoV-2 cases and deaths across the globe during current pandemic. 
Source adapted from (https://covid19.who.int/). [accessed 2020-06-30].
Figure 3. 
Total number of daily new confirmed SARS-CoV-2 cases and deaths in India during current pandemic. Source 
adapted from (https://covid19.who.int/). [accessed 2020-06-30].
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3. Historical perspectives of CP
Serum therapy was the only effective treatment option for infectious diseases 
prior to the discovery of antibiotics. In the year 1890, serum therapy was founded 
by Emil von Behring. The use of serum blood therapy has been proposed for 
treating diphtheria. At the same time Behring and Kitasato developed an effective 
therapeutic serum against tetanus.
Documented reports of the Spanish flu H1N1 pandemic (1918–1920) stated 
that transfusion of influenza-convalescent human blood products (whole blood, 
plasma, or serum) reduced morbidity and mortality. Hence, convalescent 
plasma could be an effective therapy during  viral outbreaks and pandemics [17]. 
Treatment of severe H1N1 infection with convalescent plasma revealed that 1 dose 
of convalescent plasma with >1:160 neutralizing antibody was successful in reduc-
ing mortality and the viral load of the respiratory tract decreased by >3log10 copies/
mL within 48 h of plasma therapy [18]. H5N1-infected BALB/c mice treated with 
H5N1-specific F(ab’)2 fragments derived from horses provided proof that passive 
immunotherapy is effective for immunologically competent and incompetent 
hosts [19].
A Lyophile serum was used effectively to prevent and/or treat many diseases 
such as measles, chickenpox, mumps, German measles, erysipelas, hemolytic 
streptococcal infections and scarlet fever [20]. Argentine hemorrhagic fever (AFH) 
caused by Junin virus is one of the few infectious viral disease in which CP admin-
istration is a specific treatment of choice that can neutralize viremia after immune 
plasma transfusion [21]. CP has been used with varied outcomes in combating Lassa 
fever and Ebola virus [22, 23]. For most viral diseases, the first week of infection 
peaks with viremia. The patient typically produces a primary immune response by 
day 10–14 followed by virus clearance.
In the SARS-CoV-1 outbreak, CP therapy was used and found to be more effec-
tive in patients who received transfusions within 14 days of the onset of symptoms 
[24]. The analysis further revealed that virus was cleared 1 day after CP transfusion, 
preceded by fever subsidence and pulmonary infiltrate resolution. CP transfusion 
may be considered as alternative treatment in cases where SARS-CoV patients 
experience severe deterioration and fail to respond to the available treatment such 
as ribavirin or methylprednisone [25].
Figure 4. 
Total number of SARS-CoV-2 cumulative cases and deaths in India during current pandemic. Source adapted 
from (https://covid19.who.int/). [accessed 2020-06-30].
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Meta-analysis by Nottingham University-World Health Organization 
Collaborating Center showed that CP containing MERS-CoV-specific antibod-
ies from recovered patients could be the most promising near-term therapy for 
infected individuals. In MERS-CoV patients, treatment with CP was restricted by 
a limited pool of donors with adequate antibody levels [26] and the usage of CP in 
three critically ill respiratory failure MERS-CoV patients in South Korea resulted in 
significant clinical improvements [27].
4. Convalescent plasma (CP)
The first and foremost important criteria for the convalescent plasma immu-
notherapy is that recovered SARS-CoV-2 donor should have high neutralizing 
antibody (nAb) titer and specific to the virus [28]. It is proposed that SARS-CoV-2 
specific nAbs may reduce the viral load, severity of diseases and further also 
increase the nAb titer level of COVID-19 patients. CP may be a potentially effective 
strategy and first line of defense against the current wreaked havoc SARS-CoV-2 
viral pandemic.
4.1 Clinical outcomes of CP
A Single dose of CP with a high concentration of nAbs rapidly reduced the viral 
load and eventually increased clinical outcomes of ten severe adult SARS-CoV-2 
patient from china by successful use of the CP immunotherapy. Single dose of 
200 mL of inactivated CP with high neutralization titer of >1:640 was transfused 
according to the WHO blood transfusion protocol. Interestingly this recent study 
showed significant increase in nAb titer level, disappearance of SARS-CoV-2 RNA 
at an undetectable level, reduction of pulmonary lesions and amelioration of 
laboratory parameters in all patients after CP transfusion. The clinical symptoms 
were improved within 3 days and the viraemia was also disappeared on 7 days of CP 
immunotherapy (Figure 5) [28].
The recent study from China over 175 patients recovered from SARS-CoV-2 
clearly showed the production of SARS-CoV-2-specific neutralizing antibodies after 
10–15 days of infection. Interestingly this study had several findings that conva-
lescent plasma recovered from SARS-CoV-2 patients specifically inhibited SARS-
CoV-2 alone, but not the SARS-CoV infection, the peak of neutralizing antibodies 
were detected in all patients after 10 days of infection and variations in nAb titers 
Figure 5. 
Comparison of serum neutralizing antibody titer before and after CP immunotherapy. [CP, Convalescent 
plasma]. Source adapted from Duan et al. [28].
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were observed as 30% of infected patients corresponds to low nAb titer (< 500), 
17% to medium-low titers (500–999), 39% to medium-high titers (1000–2500) and 
14% to high nAb titers (>2500). Moreover, the elderly and middle-aged patients 
had substantially higher plasma nAb titers and spike-binding antibodies than young 
aged SARS-CoV-2 infected patients [29]. Further this study showed the noteworthy 
findings of CP immunotherapy can be specifically used for the prevention and 
treatment of SARS-CoV-2.
Five critical patients from china with SARS-CoV-2 and acute respiratory distress 
syndrome (ARDS) had eventually recovered after CP immunotherapy. Clinically 
significant improvement of four out of five were reported promptly. This recent 
study showed increase in nAb titer level (Figure 6) and titers of IgG and IgM in the 
sera got increased in a time-dependent manner after convalescent plasma transfu-
sion. It was observed that the Ct value of all patients seems to be negative after 
12 days of transfer of CP immunotherapy [30].
Ye et al. reported an increase in anti-SARS-CoV-2 nAb titers and further increase 
in IgG and IgM antibodies. CP transfusion resulted in the resolution of ground glass 
opacities and consolidation in patients lung. The clinically significant outcome of 
this study is that all the six SARS-CoV-2 infected patients were found negative in 
throat swab analysis by real-time PCR assay due to reduction in the viral load after 
CP immunotherapy [31].
SARS-CoV-2 infected patients over the age of sixty years received CP treatment 
had a significantly prolonged recovery time estimated by viral clearance (10 to 
29 days) compared to younger patients, who recovered from the disease in less than 
a week after receiving CP immunotherapy [32].
The level of specific neutralizing antibody against SARS-CoV peaked at 
4 months and gradually disappearing to an undetectable level of 25.8% (IgG) and 
16.1% (nAbs) in serum after 3 years of recovery [33]. Similarly, MERS-CoV infected 
patients showed a low prevalence of 2.7% IgG seroreactivity and the antibodies titer 
dropped rapidly within 3 months of recovery [26].
Even though the level of specific nAb titers in sera were decreasing gradually, it 
is also possible to isolate potent neutralizing human monoclonal antibodies (mAbs) 
from memory B cell repertoire of convalescent patients against SARS-CoV [34] 
and SARS-CoV-2 [35]. The detailed possible FDA approved protocol for convales-
cent plasma immunotherapy transfusion was discussed in this recent studies for 
 SARS-CoV-2 [36] and Ebola virus [37]. The possible protocol of CP immunotherapy 
transfusion for COVID-19 patients is depicted in Figure 7.
Figure 6. 
Comparison of serum neutralizing antibody titer before and after CP immunotherapy. [CP, Convalescent 
plasma]. Source adapted from Shen et al. [30].
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4.2 Immunomodulatory effects
In a mouse model study, SARS-CoV pathogenesis is directly regulated by 
complement and its absence showed significantly reduced respiratory disease, 
decreased neutrophilia in their lungs, reduced systemic inflammation and viral load 
remains unchanged in a complement-deficient mice. Since SARS-CoV pathogenesis 
was mainly immune-driven, inhibiting the complement signaling pathway after 
SARS-CoV infection is also an effective immune therapeutic strategy [38]. By 
scavenging complement fragments of C3a and C5a, intravenous immunoglobulin 
prevents immune damage and restricts the development of immune complexes [39]. 
Similarly, passive antibody transfer may limit the cellular damage induced by the 
activation of complement cascade in an excessive inflammatory area.
Figure 7. 
Schematic representation of CP immunotherapy for SARS-CoV-2 patients highlighting the major steps.
Figure 8. 
A brief overview of possible mechanisms of action of CP immunotherapy. [nAb, neutralizing antibody titer; 
ADCC, antibody-dependent cellular cytotoxicity; ADCP, antibody-dependent cell mediated phagocytosis; 
CDC, complement-dependent cytotoxicity; ADE, antibody-dependent enhancement.
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IgG therapy controls the cytotoxic effect of T-cells by modulating the balance 
of Th17/Treg and decreasing CD8+ T cells and Th17 cells [40]. The possible mecha-
nisms of action of CP immunotherapy are summarized in Figure 8.
Feline coronaviruses, HIV and dengue viruses use an antibody-dependent 
enhancement (ADE) phenomenon to take advantage of pre-existing poorly nAbs 
to effectively infect host target cells in order to combat anti-viral humoral immune 
response [41].
In vitro assays with human promonocyte cell lines HL-CZ demonstrated that 
ADE was primarily mediated by highly diluted antibodies against spike proteins, 
significantly increasing the rate of apoptosis of SARS-CoV infected cells [42].
5. Adverse effects
Previous studies did not find any adverse effects associated with CP immuno-
therapy during historical influenza A (H1N1), SARS-CoV, or MERS-CoV epidemics 
[18, 26, 43]. In case of Ebola, it was associated with mild adverse effects such as 
fever, nausea, skin erythema, and no other significant adverse events were found 
[44]. A self-limited facial erythema occurred in 2 out of 10 SARS-CoV-2 infected 
patients with no major adverse events found during the transfusion study [28]. The 
therapy was well tolerated in most of the patients while some reported only mild 
adverse effects. Several studies of SARS-CoV-2 have shown that CP immunotherapy 
is safe and not associated with any significant adverse effects.
6. Limitations
The risk of Hepatitis B virus, Hepatitis C virus and HIV disease transmission 
through the donated plasma should be thoroughly investigated before CP transfu-
sion. The nucleic acid test for this viruses is strictly mandatory to ensure the safety 
of SARS-CoV-2 infected CP recipients [45].
Vaccine development should consider ADE phenomenon in COVID-19 patients 
as ADE may promote intensity of infection and administration of CP in those 
coronaviruses endemic areas should be carried out with caution since ADE appears 
to be harmful to actively infected patients [46].
All the recovered patients received not only the CP transfusion but also other 
standard care like antiviral treatment. As a consequence, these antiviral agents may 
also lead to the subsequent recovery of patients, or may synergize with the thera-
peutic effect of CP, which cannot be ruled out.
Taken together, these studies suggested that convalescent plasma from recently 
recovered patients with high neutralizing antibody titers against SARS-CoV-2 
would be more effective for CP immunotherapy. A warranted random clinical trial 
in larger groups is required for dose optimization and to overcome possible adverse 
side effects of CP immunotherapy.
Furthermore, the kinetics of nAbs titers against SARS-CoV-2 need to be criti-
cally evaluated because of neutralizing antibodies represented short term humoral 
immune response.
7. Conclusion
The clinical trials of Convalescent plasma therapy conducted/initiated against 
SARS-CoV-2 pandemic across the world are getting increased day-by-day due to the 
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significant outcomes of infected patients with a high positive recovery rate when 
compared to all other modes of treatment against SARS-CoV-2 pandemic crisis. In 
SARS-CoV-2, many reports have shown that administration of CP immunotherapy 
is safe with significant potential efficacy and it was not associated with any major 
adverse events. Even in the autoimmune conditions also CP is considered to be safe. 
Thus, CP immunotherapy is considered as classical and historically noteworthy 
candidate to be further re-evaluated as a most suitable therapeutic option against 
SARS-CoV-2 pandemic.
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